Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 29;12:752892. doi: 10.3389/fendo.2021.752892

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Cherian, Al-Khairi, Jamal, Al-Sabah, Ali, Dsouza, Alshawaf, Al-Ali, Al-Khaledi, Al-Mulla, Abu-Farha and Abubaker

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Correlation analysis between irisin and various molecules associated with bone remodeling. (A) Osteoactivin, (B) Osteoprotegerin (OPG), (C) Osteonectin (SPARC), (D) Syndecan-4 levels in plasma. Performed on the non-diabetic individuals age adjusted. Irisin level in plasma was determined using enzyme linked immunosorbent assay (ELISA), a customized multiplex bone panel was used to assess the level of various osteogenic molecules. Diabetes was defined by fasting plasma glucose ≥ 126mg/L (7 mmol/L). Spearman correlation coefficient was used to determine the association of irisin with the different osteogenic factors. Statistical assessment was 2-sided and considered statistically significant at **p ≤ 0.01.